Eckert & Ziegler stock steadies after Q2 2026 results while valuation gap persists
Published on 08/19/2026 at 17:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eckert & Ziegler SE stock (ISIN DE0005659700) is trading in the low-teens in EUR as of August 18, 2026, following the company’s presentation of its Q2 2026 results, with the share price still well below the average analyst target level and highlighting a persistent valuation gap for investors.
Q2 2026 earnings underpin the story
In its Q2 2026 reporting, Eckert & Ziegler SE discussed operating performance and outlook in detail during an earnings call held on August 12, 2026, providing investors with fresh insight into its radioisotope-focused businesses. The Q2 call centered on the latest quarterly trends and how management sees demand for nuclear medicine and industrial radiation applications developing over the rest of 2026.
Q2 2026 is the most recent reported quarter available ahead of late August 2026, making it the key reference point for fundamentals in the current assessment of Eckert & Ziegler stock. This quarter sits well within the nine-month freshness window relative to August 19, 2026, so figures from this reporting period are relevant for investors who are trying to understand the company’s current earnings power and growth trajectory.
The Q2 2026 results presentation on August 12, 2026 packaged the latest revenue and profit trends in a way that allows comparison with previous quarters and with management’s guidance for the full year 2026. Investors looking for context on trends in margins, cash flow and capital expenditure in Q2 2026 rely on this presentation as the primary dataset for the current year.
Share price and valuation gap
On the market side, Eckert & Ziegler SE’s Xetra listing shows a last closing price of 13.59EUR for August 17, 2026, with the trading session recording a change of -0.44 percent and a volume of 97,147 shares; the day before, a quote of 13.50EUR was associated with a change of -0.66 percent and a volume of 92,329 shares, illustrating recent modest downward moves from the mid-teens in EUR. The Tradegate quotation on August 18, 2026 recorded a price of 13.37EUR and a daily move of -1.69 percent, while a Tradegate overview on August 19, 2026 shows a live price indication of 13.30EUR with a daily performance of -0.52 percent and a year-to-date change of -12.21 percent, underlining that the share has lost double-digit ground since the start of 2026 and is trading closer to its lower trading range for the year.
Against this price context, a market-data overview lists an average target price of 21.60EUR for Eckert & Ziegler SE, implying an upside gap of 8.01EUR compared with the last Xetra close of 13.59EUR on August 17, 2026; this corresponds to a potential increase of around 59 percent if the share were to reach the average target. This quantified difference between the current trading level in the low-teens in EUR and the target price in the low-twenties in EUR gives investors a clear sense of how far the stock still sits below the valuation expectations embedded in analyst models.
From a short-term perspective, recent daily changes of -0.44 percent and -0.66 percent on Xetra and -1.69 percent on Tradegate show that Eckert & Ziegler shares have been under slight pressure around mid-August 2026 but without extreme volatility. The combination of a year-to-date performance of -12.21 percent and a sizable gap to the 21.60EUR average target price suggests that the stock is in a consolidation phase where fundamental news from quarters like Q2 2026 will be important for determining whether the gap can narrow.
Analyst and guidance context
The Q2 2026 results presentation explicitly addresses how the company’s operating performance lines up with its guidance for full-year 2026, covering revenue growth, profitability and investment plans. With Q2 2026 now fully reported, analysts have an updated set of figures for the half year to refine estimates for metrics such as full-year revenue, EBITDA and net income, and to adjust their target prices and recommendation stances if needed.
The presence of an average target price of 21.60EUR, compared to the Xetra closing price of 13.59EUR on August 17, 2026, reflects that the consensus view embeds expectations of stronger earnings or margin expansion over time than the market price currently discounts. If Q2 2026 showed year-on-year growth at the level management targeted in earlier guidance, this would support the higher valuation implied by the target price; conversely, any slowdown in the quarter would raise questions about whether the 21.60EUR average target remains realistic.
For investors, the crucial comparison is between current quarter performance and previous periods, and between guidance and actual delivery. The Q2 2026 call on August 12, 2026 therefore serves as a key reference event, spelling out management’s narrative for the rest of the year and giving analysts the inputs they need to confirm or adjust the current average target price and the spread between that target and the prevailing market price in the low-teens in EUR.
Radioisotope solutions for medicine and industry
A representative example of Eckert & Ziegler SE’s business model is its supply of radioisotopes and related components for nuclear medicine, which are used in diagnostic imaging and cancer therapy. These medical radioisotopes are produced under strict regulatory and quality standards and delivered to hospitals, clinics and radiopharmacies, forming a recurring revenue stream tied to patient volumes and clinical demand.
Beyond nuclear medicine, Eckert & Ziegler SE also provides isotope technologies for industrial applications such as material testing, calibration and process control. These solutions make use of radiation sources to measure thickness, density or composition in manufacturing processes, helping customers maintain product quality and compliance with technical standards.
The combination of medical radioisotope products and industrial radiation applications gives Eckert & Ziegler SE exposure to both healthcare trends and industrial investment cycles. As Q2 2026 results and subsequent quarters come in, investors will watch how revenue from these segments evolves and whether growth in nuclear medicine can offset any cyclical softness on the industrial side.
Stock performance into late August 2026
As of the most recent completed Xetra trading session on August 17, 2026, Eckert & Ziegler SE closed at 13.59EUR after a daily move of -0.44 percent, while Tradegate indicated a price of 13.37EUR on August 18, 2026 and a real-time level of 13.30EUR with a daily change of -0.52 percent and a year-to-date performance of -12.21 percent on August 19, 2026. This price constellation positions Eckert & Ziegler stock below the average target price of 21.60EUR and signals that the market remains cautious despite the Q2 2026 results and the long-term nuclear medicine growth story.
Read more
More on Eckert & Ziegler SE stock and its investor information can be found via the company’s investor relations section or detailed earnings call documentation for Q2 2026.
Fact box
Company: Eckert & Ziegler SE
ISIN: DE0005659700
Ticker: EUZ
Exchange: Xetra
Price (as of August 17, 2026, Xetra close): 13.59EUR
Sector / Industry: Health care equipment and services, nuclear medicine and industrial radiation solutions
Index membership: Not specified in the available price overview
